Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti^® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes.

Read more at globenewswire.com